2024
ACLY and ACSS2 link nutrient-dependent chromatin accessibility to CD8 T cell effector responses
Kaymak I, Watson M, Oswald B, Ma S, Johnson B, DeCamp L, Mabvakure B, Luda K, H. E, Lau K, Fu Z, Muhire B, Kitchen-Goosen S, Vander Ark A, Dahabieh M, Samborska B, Vos M, Shen H, Fan Z, Roddy T, Kingsbury G, Sousa C, Krawczyk C, Williams K, Sheldon R, Kaech S, Roy D, Jones R. ACLY and ACSS2 link nutrient-dependent chromatin accessibility to CD8 T cell effector responses. Journal Of Experimental Medicine 2024, 221: e20231820. PMID: 39150482, PMCID: PMC11329787, DOI: 10.1084/jem.20231820.Peer-Reviewed Original ResearchConceptsAcyl-CoA synthetase short-chain family member 2Acetyl-CoA productionATP citrate lyaseChromatin accessibilityAcetyl-CoAEnzyme ATP citrate lyaseFamily member 2Function in vivoCoordination of cellular metabolismTCA cycleMetabolic nodesGene locusCitrate lyaseT cell effector responsesHistone acetylationCellular metabolismEffector functionsCD8 T cellsResponse to infectionMember 2ChromatinEffector responsesMetabolic substratesT cell response to infectionT cells
2014
Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM. Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ. Cancer Research 2014, 74: 3205-3217. PMID: 24736544, PMCID: PMC4063281, DOI: 10.1158/0008-5472.can-13-3461.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigen-Presenting CellsAntineoplastic AgentsCD40 LigandCD4-Positive T-LymphocytesDrug Screening Assays, AntitumorIndolesInterferon-gammaMacrophagesMelanoma, ExperimentalMiceMice, TransgenicMutation, MissenseProto-Oncogene Proteins B-rafSignal TransductionSkin NeoplasmsSulfonamidesTumor MicroenvironmentConceptsTumor-infiltrating lymphocytesIFNγ expressionMyeloid cellsImmune stimulatory microenvironmentTh1 effector functionRegulatory T cellsAgonistic CD40 antibodyImmune-related changesTumor-bearing miceSuppress tumor growthIFNγ blockadeImmunologic changesAntitumor immunityAntitumor responseCD40 antibodyTumor regressionT cellsBRAF inhibitorsMurine modelEffector functionsImmunosuppressive featuresAntitumor effectsHost immunityMelanoma growthTumor growth